TY - JOUR
T1 - Phenotypic clustering analysis of patients rejected for mitral valve interventions
T2 - implications for future transcatheter technologies
AU - CHOICE-MI Investigators
AU - Ludwig, Sebastian
AU - Coisne, Augustin
AU - Hamzi, Kenza
AU - Ben Ali, Walid
AU - Scotti, Andrea
AU - Koell, Benedikt
AU - Duncan, Alison
AU - Makkar, Raj
AU - Akodad, Mariama
AU - Bleiziffer, Sabine
AU - Nickenig, Georg
AU - Kaneko, Tsuyoshi
AU - Ruge, Hendrik
AU - Adam, Matti
AU - Sondergaard, Lars
AU - Dahle, Gry
AU - Taramasso, Maurizio
AU - Walther, Thomas
AU - Kempfert, Joerg
AU - Obadia, Jean François
AU - Chehab, Omar
AU - Tang, Gilbert H.L.
AU - Goel, Sachin
AU - Fam, Neil
AU - Denti, Paolo
AU - Praz, Fabien
AU - Von Bardeleben, Ralph Stephan
AU - Hausleiter, Jörg
AU - Latib, Azeem
AU - Conradi, Lenard
AU - Modine, Thomas
AU - Pezel, Théo
AU - Granada, Juan F.
AU - Blankenberg, Stefan
AU - Kalbacher, Daniel
AU - Schofer, Niklas
AU - Vincentelli, André
AU - Sudre, Arnaud
AU - Longère, Benjamin
AU - Webb, John G.
AU - Blanke, Philipp
AU - Rudolph, Tanja K.
AU - Friedrichs, Kai
AU - Weber, Marcel
AU - Tanaka, Tetsu
AU - Vogelhuber, Johanna
AU - Shah, Pinak
AU - Harloff, Morgan
AU - Lange, Rüdiger
AU - Ochs, Laurin
N1 - © The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
PY - 2025/8/1
Y1 - 2025/8/1
N2 - Aims Although several treatment options are available for patients with severe mitral regurgitation (MR), a significant proportion of patients remain ineligible for any mitral valve (MV) intervention. We aimed to analyse the phenotypic characteristics of surgical high-risk patients ineligible for MV interventions using an unsupervised phenotypic clustering approach. Methods and results Between 2014 and 2022, the CHOICE-MI registry included 984 patients with MR undergoing screening for transcatheter MV replacement at 33 international sites. For this study, only patients with screening failure receiving medical therapy alone were included. Patients receiving transcatheter or surgical treatment were excluded. A cluster analysis using K-means was performed on baseline clinical, demographic, and imaging variables to identify different patient phenotypes. Among 284 patients with MR (77.4 ± 8.82 years, 56.0% female, EuroSCORE II: 6.6 ± 5.8%) considered ineligible for any MV intervention, two clinically distinct phenogroups (PGs) were identified using unsupervised hierarchical clustering of principal components: PG1, elderly women with primary MR, preserved left ventricular function, and annular calcification; and PG2, patients with secondary MR, advanced heart failure, and high prevalence of comorbidities. One-year all-cause mortality did not differ between the PGs (PG1: 21.4%, PG2: 23.4%, P = 0.89). Predictors of mortality were albumin, renal function, and extracardiac arteriopathy for PG1 and albumin, coronary artery disease, and prior myocardial infarction for PG2. Conclusion This study identified two major subgroups among patients ineligible for mitral interventions showing profound differences in clinical and anatomical profiles. Identifying these factors may drive technological evolution to address the unmet clinical need for therapeutic options in MR patients. ClinicalTrials.gov identifier NCT04688190 (CHOICE-MI Registry).
AB - Aims Although several treatment options are available for patients with severe mitral regurgitation (MR), a significant proportion of patients remain ineligible for any mitral valve (MV) intervention. We aimed to analyse the phenotypic characteristics of surgical high-risk patients ineligible for MV interventions using an unsupervised phenotypic clustering approach. Methods and results Between 2014 and 2022, the CHOICE-MI registry included 984 patients with MR undergoing screening for transcatheter MV replacement at 33 international sites. For this study, only patients with screening failure receiving medical therapy alone were included. Patients receiving transcatheter or surgical treatment were excluded. A cluster analysis using K-means was performed on baseline clinical, demographic, and imaging variables to identify different patient phenotypes. Among 284 patients with MR (77.4 ± 8.82 years, 56.0% female, EuroSCORE II: 6.6 ± 5.8%) considered ineligible for any MV intervention, two clinically distinct phenogroups (PGs) were identified using unsupervised hierarchical clustering of principal components: PG1, elderly women with primary MR, preserved left ventricular function, and annular calcification; and PG2, patients with secondary MR, advanced heart failure, and high prevalence of comorbidities. One-year all-cause mortality did not differ between the PGs (PG1: 21.4%, PG2: 23.4%, P = 0.89). Predictors of mortality were albumin, renal function, and extracardiac arteriopathy for PG1 and albumin, coronary artery disease, and prior myocardial infarction for PG2. Conclusion This study identified two major subgroups among patients ineligible for mitral interventions showing profound differences in clinical and anatomical profiles. Identifying these factors may drive technological evolution to address the unmet clinical need for therapeutic options in MR patients. ClinicalTrials.gov identifier NCT04688190 (CHOICE-MI Registry).
KW - clustering
KW - medical therapy
KW - mitral regurgitation
KW - non-supervised machine learning
KW - transcatheter mitral valve replacement
KW - Severity of Illness Index
KW - Risk Assessment
KW - Humans
KW - Male
KW - Patient Selection
KW - Cardiac Catheterization/methods
KW - Mitral Valve Insufficiency/surgery
KW - Phenotype
KW - Heart Valve Prosthesis Implantation/methods
KW - Aged, 80 and over
KW - Female
KW - Registries
KW - Aged
KW - Cluster Analysis
UR - https://www.scopus.com/pages/publications/105012248954
UR - https://www.scopus.com/inward/citedby.url?scp=105012248954&partnerID=8YFLogxK
U2 - 10.1093/ehjci/jeaf141
DO - 10.1093/ehjci/jeaf141
M3 - Article
C2 - 40329826
AN - SCOPUS:105012248954
SN - 2047-2404
VL - 26
SP - 1452
EP - 1463
JO - European Heart Journal Cardiovascular Imaging
JF - European Heart Journal Cardiovascular Imaging
IS - 8
ER -